DoE-Assisted Development of a Novel Glycosaminoglycan-Based Injectable Formulation for Viscosupplementation

The aim of the present work was the development of a novel glycosaminoglycan (GAG)-based injectable formulation intended for intra-articular administration that should best mimic the healthy synovial fluid. Hyaluronic acid (HA) was chosen among GAG polymers, since it is the most abundant component o...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2020-07, Vol.12 (7), p.681
Main Authors: Cicognani, Marta, Rossi, Silvia, Vecchi, Gabriele, Giori, Andrea Maria, Ferrari, Franca
Format: Article
Language:English
Subjects:
Aqueous solutions
Arthritis
Behavior
Cartilage
Connective tissue
Design of experiments
DoE approach
Fluids
Hyaluronic acid
Lubricants & lubrication
Molecular weight
phosphatidylcholine
Physiology
Rheology
Sodium
Tribology
tribology measurements
viscoelastic injectable solutions
Viscoelasticity
Viscosity
viscosupplementation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the present work was the development of a novel glycosaminoglycan (GAG)-based injectable formulation intended for intra-articular administration that should best mimic the healthy synovial fluid. Hyaluronic acid (HA) was chosen among GAG polymers, since it is the most abundant component of the synovial fluid. A DoE (Design of Experiment) approach was used for the development of a formulation containing two HA (very high (VHMW) and low (LMW) molecular weight) grades. The rationale for this choice is that so far, no commercial product based on a single HA grade or even on binary HA mixture possesses optimal viscoelastic properties in comparison with healthy synovial fluid. A full factorial design was chosen to investigate the influence of concentration and relative fraction of the two polymer grades (retained as factors of the model) on formulation functional (viscosity and viscoelastic) properties, which are considered response variables. Thanks to the DoE approach, the composition of the optimized HA formulation was found. The addition to such formulation of an injectable grade fat-free soy phospholipid, which was rich in phosphatidylcholine (PC), resulted in improved lubrication properties. The final HA + PC formulation, packaged in pre-filled sterile syringes, was stable in long-term and accelerated ICH (International Council for Harmonisation) storage conditions. The overall results pointed out the formulation suitability for further steps of pharmaceutical developments, namely for the passage to pilot scale.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics12070681